BOSTON and NEW HAVEN, Conn. — November 5, 2025 — Leads & Copy —
Normunity, a biotechnology company, has dosed the first patient in a Phase 1 clinical trial (NCT07182149) for its lead drug candidate, NRM-823, a first-in-class T cell engager. The trial will assess the safety, tolerability, and initial efficacy of NRM-823, both as a monotherapy and in combination with immune checkpoint inhibition, in patients with advanced or metastatic refractory solid tumors.
Rachel Humphrey, MD, CEO of Normunity, noted that the trial marks an important milestone, bringing a potentially transformational cancer therapy to patients and transitioning the company to a clinical stage. Melinda Merchant, MD, PhD, CMO, added that NRM-823’s design allows the body’s immune system to target tumor cells precisely. Preclinical data have shown anti-tumor activity and a favorable safety profile.
Kathryn Morris, The Yates Network LLC, 914-204-6412, kathryn@theyatesnetwork.com
Source: Normunity
